Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
DANBURY, Conn., July 6 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, U.S.A. next week.
#51, Oral session on peptides and proteins, Monday July 12, 2010 4:00 PM (PT) "'Smart' Basal Insulin Formulation that Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine," to be presented by N. Kashyap, Biodel Inc.
#373, Poster session on peptides and proteins, Monday July 12, 2010 1:00 PM - 2:00 PM (PT) "Effect of EDTA Concentration on Ultra-Rapid Action of VIAject® in Diabetic Miniature Swine," to be presented by Dr. R. Pohl, Biodel Inc.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product